Genmab — November 2013
-
-
J&J får hurtig FDA-godkendelse
FDA har godkendt et lægemiddel fra Johnson & Johnson til behandling af lymfekræft efter en ualmindelig kort evalueringsperiode på blot fire måneder. Det er blot anden gang, at et lægemiddel bliver godkendt under FDAs specielle Breakthrough-program.
(medwatch.dk)
-
Ibrutinib sælges for 20$ pr. pille
det svarer til 130.000$ om året pr. patient i Mantle cell så vidt jeg kan se !!! 
-
the agency's accelerated approval program, which allows the FDA to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients
-
Among the 19 patients evaluable for response, overall response rate was 94%, with CR in 17 patients, partial remission in one patient and progressive disease after the second cycle in one patient; 15 out of 15 patients evaluable for minimal residual disease in the BM showed molecular remission.
-
-
Godt at Arzerra kun jagter R/R DLBLC label, for SPectrums nye stof Marqibo deler satme tæsk ud i frontline DLBLC. TJek lige de har 10 years follow up data: https://ash.confex.com/ash/2013/webprogram/Paper55944.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind